A hot area of investigation concerns interactions between bile...

A hot area of investigation concerns interactions between bile salts, gut microbiota, and immune checkpoint inhibitor response.
For example, increased PD-1 activity has been reported following FMTs.

Dr. Barry Marshal at the University of Western Australia in Perth already got a Nobel Prize for his work on microbiome and ulcers.
Maybe he would like another prize determining the role of microbiome in immune therapy. Analysis of microbiomes and bile acid profiling at the beginning and end of IMM's trials may yield significant information. Dr. Marshall or another investigator can set up a study without altering the treatment protocols. Determining the role of the microbiome and bile acids in immune treatment outcomes will attract interest and may yield new treatments for even better results.

Wish IMM considers this addition to their trials.